Physiological Effect: Decreased Cholesterol Absorption
✉ Email this page to a colleague
Drugs with Physiological Effect: Decreased Cholesterol Absorption
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aurobindo Pharma | EZETIMIBE | ezetimibe | TABLET;ORAL | 209838-001 | Aug 25, 2017 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Accord Hlthcare | EZETIMIBE | ezetimibe | TABLET;ORAL | 211550-001 | Oct 26, 2018 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Sandoz | EZETIMIBE | ezetimibe | TABLET;ORAL | 203931-001 | Jun 12, 2017 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Hetero Labs Ltd Iii | EZETIMIBE | ezetimibe | TABLET;ORAL | 210859-001 | Jul 26, 2022 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |